The ESMO 2025 Congress is a major global oncology event organized by the European Society for Medical Oncology (ESMO).
It is taking place at Messe Berlin in Berlin, Germany, from October 17 to 21, 2025. The congress features a comprehensive scientific and educational program designed to foster exchange and debate in translational cancer science, showcasing potentially practice-changing data, and stimulating multidisciplinary discussions to improve cancer treatment options.
“Sarcoma meeting at ESMO – European Society for Medical Oncology 2025!
New initiative is coming… stay tuned.”
“Super excited to be at ESMO Congress 2025 this week! I’ll be presenting my poster, “Global trends in CNS tumor clinical trials: A decade of data from 950 interventional studies,” on 20 October, 12:00–12:45, in Hall 25. If you’re attending, please drop by. I would love to connect.
Grateful to the team and collaborators who made this analysis possible.
Poster session: 20 Oct | 12:00–12:45
Location: Hall 25
See you there!”
“If you’re at ESMO, let’s connect!
We’ll be sharing real-world, scalable solutions from Egypt across policy, supportive care, and patient experience. Would love your insights, challenges, and collaboration ideas.
Sunday, 19 Oct | 12:00 | Poster Area, Hall 25
Policy Track:
- 2304P—Public-private-NGO partnership boosts early breast cancer detection in Egypt: Lessons for scaling across LMICs
- 2321P—Hospital time impact of subcutaneous vs intravenous anti-HER2 therapies in Egypt: A time-motion study
- 2315P—Governmental pharma-industry partnership transforms Egypt’s breast cancer patient journey (2019–2024)
Supportive Care Track:
- 2885P—A pragmatic multi-component program enhances adherence to oral anticancer therapy: Prospective results from BCCC
- 2893P—Marital dynamics among young married women with breast cancer: A cross-sectional study
Cancer Nursing:
- CN125—Arabic validation of the hot flushes diary for young breast cancer survivors: A cross-cultural psychometric study
Stop by, say hello, and let’s turn evidence into action.”
“We did it! Our Breast Unit at ULS Lisboa Ocidental has performed its first endoscopic mastectomy, adopting a revolutionary technique that is transforming breast cancer patient care globally.
We’re witnessing a remarkable convergence of advanced surgical techniques and personalized medicine that is delivering unprecedented patient outcomes. Recent research shows how endoscopic mastectomy, combined with genomic-guided decision-making, represents the future of individualized breast cancer care.
Personalized Surgical Oncology and Endoscopic Excellence: 2025 Evidence
A comprehensive meta-analysis of 2,612 patients shows:
- Oncological Safety: Equivalent cancer outcomes vs. conventional surgery (52-month follow-up)
- Superior Aesthetics: 88% improved cosmetic satisfaction (OR = 1.88; P = 0.020)
- Reduced Complications: 81% decrease in postoperative necrosis with single-incision technique
- Precision Delivery: 4 cm incisions enable surgical precision
Our achievement positions ULS Lisboa Ocidental at the forefront of breast surgical innovation, aligning us with leading national and international centers in advancing minimally invasive oncological surgery.
This milestone represents our commitment to:
- Evidence-based surgical innovation
- Patient-centered personalized care
- Integration of cutting-edge technologies
- Superior aesthetic and functional outcomes
Future Vision
Next-generation sequencing for intraoperative genomic profiling
Advanced AI algorithms for surgical outcome prediction
Expanded applications across diverse patient populations
The Bottom Line
This achievement marks a new era for our patients: precision medicine defines surgical excellence.
At ULS Lisboa Ocidental, we’re not just adopting innovative techniques; we’re participating to co-create the future of personalized breast cancer care.
Every surgical decision needs to be tailored to each patient’s unique tumor biology, risk profile, and genomic fingerprint, ensuring optimal outcomes with minimal invasiveness.
Congratulations to our entire Breast team for this remarkable achievement! Guys, we have just started!
- A hudge thank you to Gauthier Rathat and his team for the training, support and friendship provided!
- A hudge thank you to Nelson Amado and Applied Medical for supporting us!”
“I am so grateful for the invitation to the ESMO25 session on the future of HTA in 🇪🇺 ! Excited to share the dialogue on the future of the policy decision making on cancer pharmaceuticals with the EU lead European Commission by providing a case study on the cancer biomarker strategy from Italy.”
“This weekend, GenesisCare España is proud to be present at two major oncology events shaping the future of cancer care:
7th Spanish Breast Congress (Congreso Español de la Mama) , where our teams are contributing to the advancement of breast cancer diagnosis, treatment and patient support, reinforcing our commitment to innovation and personalized care.
ESMO Congress 2025 in Berlin, joining the global oncology community to share research, explore new therapeutic frontiers, and strengthen collaborations that drive progress for patients everywhere.
From Madrid to Berlin, one shared mission unites us: transforming cancer care through science, technology, and compassion ”
“Personally, for this ESMO25, I was most excited to see the results of DESTINY Breast05 – T-Dxd vs T-DM1 in early HER2-enriched breast cancer with residual disease.
Unsurprisingly, T-Dxd outperforms T-DM1 in this setting as well. The focus will now be on implementation – toxicity, CT monitoring and access.
Interestingly, the median study duration (9.8 vs 9.7 months) was similar in both arms but of course, pneumonitis rates were much higher (9.6 vs 1.6%), as well as nausea. The majority of ILD cases were grade 1 or 2 and reversible.
Also interesting that pneumonitis rates were similar whether radiotherapy was given sequentially or concurrently. Potentially practice-changing results with significant real-world considerations.”
“Happy to share my first time as co-chair and speaker at ESMO2025 in an amazing educational session on high grade NENs and honored to have discussed a challenging topic on high proliferative lung NETs together with a stimulating faculty!
Great ESMO with my colleagues Chiara e Lorenzo from IEO and more friends and fellows from all around the world.”
“I’ll have my take on the most important trials from ESMO25 soon on my regular ESMO roundup video, so stay tuned.
In the meantime, please consider these general points before you start claiming every trial with a P < 0.05 is the new standard of care. You don’t need to think critically to claim that everything is practice-changing.
- Prognostic biomarker is not the same as predictive biomarker. A good prognostic marker alone doesn’t make a good surrogate. I’m talking path CR rates and ctDNA. They are good prognostic markers but not predictive or a surrogate. https://lnkd.in/gDrW5cgh
- Perioperative trials! We need to know the contribution of components. We are overtreating our patients. Having fatal AEs or life-altering AEs in a curative setting is not “acceptable” or “well tolerated”. Even 1 additional cycle is too much if it’s not adding any benefit. https://lnkd.in/gSc9CTdu
- Don’t inflate benefit by quoting relative risk reduction when absolute risk reduction is dismal or baseline (control arm) risk is pretty low to begin with.
- When we are running 1000s of trials of immunotherapies, of course, we will get many false positives (we wouldn’t know which one). Slicing an individual trial data further into dozens of subgroups further intensifies this risk of seeing things where there is nothing to see. So don’t make any clincal inference based on these subgroup analysis.”
Title: Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward
Authors: Abhenil Mittal, Myung Sun Kim, Shenna Dunn, Kristin Wright, Bishal Gyawali
Read the Full Article.
Title: ‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent
Authors: Garth W. Strohbehn, Bishal Gyawali
Read the Full Article.
“The clock is ticking…
If at ESMO2025 come to Hall 6.1 “Bochum” and be among the first to see the 5th edition of the European Code against cancer – launched in English at 10h15 today.”
“Kicking off another powerful day at ESMO25!
Today, EORTC CEO Denis Lacombe will address two key questions:
- Are we using therapies in the most effective way?
- And are we designing trials that truly reflect the diversity of patients?
These sessions highlight the need for research that is both scientifically sound and socially responsible.
We’re proud to contribute to the dialogue on making cancer research more effective and inclusive.”
“Great team ESMO 2025 in Berlin!”
ESMO:
“Peri-operative enfortumab vedotin plus pembrolizumab significantly prolonged event-free survival and overall survival when added to standard surgery compared with surgery alone in cisplatin-ineligible patients with muscle-invasive BladderCancer (MIBC) in the phase III KEYNOTE-905/EV-303 trial. The field continues to evolve rapidly, with other phase III ClinicalTrials ongoing.
Read more in the ESMO Daily Reporter.”
“Today during the ESMO YOC session, we discussed development opportunities for students and young doctors.
Together with my amazing mentor Pawel Sobczuk we worked on a review about student initiatives worldwide and how they shape the future of oncology. It’s inspiring to see how young professionals around the globe are driving innovation, education and collaboration in this field.
In Poland, we’re proud to have Studenckie Onko-Forum, a community that connects, educates and motivates young people interested in oncology.
Tomorrow at 12:00, we’ll be presenting our review during the Policy Poster Session — join us to continue the discussion about student engagement and the power of collaboration across borders.”
“The survey on understanding the gaps in IO-toxicity management across European countries was presented today by Maggie O’Connor I missed the prime time at the poster session but not the important key takeaways:
- Gaps in the knowledge on the usage of 2nd line immunosuppressants
- A need for collaborative networks between oncologists and organ specialists for proper IO toxicity management
A huge thanks to the IO-tox ‘working group’ emerging from the ESMO – European Society for Medical Oncology Supportive care faculty and the Practising oncology work group.”
“What an incredible energy at this year’s ESMO25 Congress in Messe Berlin 🇩🇪 ! The first day has already been packed with inspiring discussions, groundbreaking research, and the chance to meet with brilliant minds from around the world. Vivek Subbiah, MD Yüksel ÜRÜN Dario Trapani raffaella casolino
Even more special was the chance to reunite with old friends and colleagues who share the same dedication to advancing cancer care. From lively debates to shared meals and laughter, these moments remind me why our work matters—it’s not just about the science. Here’s to more collaboration, learning, and making a difference together.”
“Honoured to co-chair and speak in the inaugural Tumour-Agnostic Track educational session at ESMO25 Congress today — alongside track chair Vivek Subbiah, MD, my co-chair Juliana Rodrigues Beal, and speakers NiamhColeman and Albrecht Stenzinger.
I discussed the landscape of tumour-agnostic immunotherapy and antibody drug conjugates, but are they ready for prime time…?
We explored the critical need for innovative trial designs, biomarker harmonisation, and, importantly, regulatory alignment—all essential to overcome real-world implementation barriers and deliver these life-extending therapies to patients with rare cancers who are still waiting.
Deeply grateful to Caitlin Delaney for allowing me to share her story on the global stage to advocate for progress in tumour-agnostic drug development.
There is much work to be done.”
“Grateful to everyone who joined our “Meet the Experts” sessions today at ESMO 2025!
Truly exciting to engage with so many clinicians and researchers who share our passion for advancing precision oncology through multi-omic molecular profiling.”
“Fondazione Policlinico Gemelli at ESMO 2025: Advancing Together Through Scientific Excellence
It is with great pride that our oncology delegation from Fondazione Policlinico Universitario Agostino Gemelli IRCCS, under the distinguished leadership of Prof. Giampaolo Tortora, participates in hashtagESMO25 Barcelona.
This congress represents more than a scientific meeting—it embodies our collective commitment to transforming cancer care through:
Knowledge Exchange in Breast Cancer: Engaging with breakthrough data from pivotal trials including DESTINY-Breast09, HORIZON-Breast01, and TROPION-Breast02, which are reshaping treatment paradigms in HER2+ and triple-negative breast cancer.
Update data in adjuvant setting in luminal with OS positive results of monarchE and iDFS and DDFS at 5y of NATALEE.
- Global Collaboration: Building bridges with international colleagues to foster multicenter research initiatives and clinical trial participation
- Scientific Dissemination: Sharing our institutional experience and contributing to the global oncology dialogue through presentations and discussions
- Innovation Transfer: Bringing cutting-edge therapeutic strategies back to our patients at Gemelli, ensuring rapid translation from bench to bedside
The future of oncology lies not in isolated excellence, but in our ability to grow together as a global scientific community. Each connection made, each insight shared, strengthens our collective mission against cancer.”
“During my incredible time at AstraZeneca, I had the privilege of contributing to regional real-world evidence efforts that helped shape our understanding of HER2-low breast cancer across the GCC.
Seeing this collaboration presented at hashtagESMO2025 fills me with pride: a true testament to the power of science, partnership, and purpose in advancing care for patients.
CHECK OUT THE POSTER 639eP !
SUPER Grateful to have worked alongside inspiring colleagues and investigators who continue to drive oncology forward.”
“TACTIVE-N: neoadj vepdeg vs. anastrazole Tumor at baseline, wk 2, and at surgery (6mo) Comparable results- Ki-67 declines by about 70% at 2 wks and further ~ 80% at surgery for both drugs 100% PgR H score decline with vepdeg.”
“Very interesting preliminary data to support the use of oral SERD (in this case giredestrant) without ovarian function suppression in premenopausal women with HR+/HER2- early Breast Cancer.”
“Flawless presentation from Miguel Zugman at ESMO25. From the podium, he presented data pertaining to MET alteration in papillary kidney cancer, shedding light on the role of chr7. Also appreciated the thoughtful discussion by Ignacio Duran, with a solid interpretation of the data.”
“Harmoni-6 LBA now out at ESMO25 Good numbers, PD-L1 pos and neg results are interesting. Probably going to go to the wire with ivonescimab until we see the results of the global trials incl Harmoni-3. With the good tox profile a small OS win will probably be enough!”
“Congrats Marc Machaalani on a phenomenal talk ESMO about soluble MadCAM-1 in mRCC A true testament to all the hard work and dedication you and co-firsts Carolina Alves Costa Silva, Renee Maria Saliby put into this project! Thrilled to see this now in press.”
“Many phase 3 trials reporting out! Need a simple way to track FDA approvals? Share and bookmark this page. It’s an excellent resource for busy clinicians, everyone in cancer drugdevelopment, and Boards prep. Below is just 1 month.”
“Excellent presentation by Dana Rathkopf on QOL from amplitude trial. Some initial decline in QOL that resolves post C1.”
“Small NF PanNETs can/should be observed
Prospective multi-centre cohort PanNETs <2cm An image is worth 1000 words For resection: NNT 276 NNH 6 No difference in OS surgery vs active surveillance Congrats on landmark work!”
“Wow. All the benefit of checkpoint inhibition in A-BRAVE (high-risk TNBC) was seen in patients with TILs ≥ 30%. No benefit with low TILs. Unbelievable that we didn’t get to see the TILs data from KN522 yet.
Hope we’ll see them soon. Congrats Maria Vittoria Dieci.”
“KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much than anything before ESMO25 pCR> 50% questions unselected surgery.
This becomes standard of care here. Questions-How would this perform in a cisplatin eligible population? Better? Can ctDNA help? How many cycles are needed? B15 and VOLGA can help here.Finally, bladder sparing trials are needed to address the need for surgery.”
“The soul of Oncology, the spirit of science: the ARON project. Thanks ESMO for allowing us to meet at ESMO25 Not easy to see a group with more scientific production in the field of GU.”
“Congrats Kinglsey Cheung for putting together an abstract for ESMO on our experiences of longer term use of selective RET inibitors addressing it toxicities and resistant mechanisms. A truly team effort involving many clinical investigators and support staff colleagues who are in the day to day care of our patients. Please check out poster 2000P virtually for more information!”
“DATO-DXd improves PFS and OS as first line therapy for patients with mTNBC not candidates for immunotherapy but no crossover. ADCs are improving outcomes (TROPION-Breast02).”
“Rahul Aggarwal showing MFS and time to castration resistance benefit of ADT and apalutamide in the PRESTO trial — important work for PSA recurrent disease. ”
“Both vepdegestrant (TACTIVE-N) and giredrestrant (EMPRESS) are neoadj window of opportunity trials to explore biomarkers and demonstrate that these two novel ETs.”
“Amazing team!Kudos to Toni Choueiri, Myriam Chalabi for fantastic scientific program all giving stellar talks across meetings leading GU field!”
“ALBATROS Trial (IFCT-2003) largest study evaluating lorlatinib after 1L-TKI therapy in ROS1 NSCLC ESMO25 ESMOAmbassadors ORR 30% mPFS 7.4 mo mDoR 20.4 mo mOS 42.3 mo Impressive CNS ORR 92%.”
“Two oral presentations on efficacy of ifinatamab in the brain and of tarlatamab by platinum free interval in SCLC. Pedro Rocha gave an elegant presentation of the data and among many other things he is an EORTC LCG Young and Early Career Investigator.”
“TROPION-Breast02: Dato-DXd vs TPC for 1L mTNBC, PDL1-/IO ineligible presented by the fabulous Rebecca Dent
control: taxane or cape or eribulin or carbo 15% DFI 0-6mo PFS 10.8 vs 5.6 mo HR 0.57, p<.0001 OS: 23.7 vs 18.7 mo ORR: 62.5vs 29.3%, DOR 12.3 vs 7.1.”
“After a year of monthly virtual meetings through the ESMO
Virtual Mentorship Programme, I finally met my mentor in person at ESMO25! Many thanks to @DrJonLim
for the inspiring guidance and to ESMO
for making this wonderful initiative possible.”
“Thank you to Chiara Cremolini for reminding providers that IO therapy in TMBhigh in MSS colorectal cancer provides NO benefit despite agnostic FDA approval. Yamaguchi et al, ESMO open, 2025. I have been reiterating this repeatedly, so IMP to use regular chemo in this setting.”
“Highly anticipated results of ENZARAD
The results speak for themselves but I think this is something Daniel E Spratt has been harping about for blanket ARSI for high risk Prostate Cancer patients.”
“In CAPItello-281, adding Capiversatib to Abi in patients with PTEN deficiency improves PFS from 26 months to 33 months as presented by Prof. Karim Fizazi.”
“Honored to join Grupo GETNE’s work, presented by J Hernando at ESMO25 Key real-world data for managing anaplastic thyroid carcinoma, a rare, challenging tumor. Multicenter collab Evidence to enhance clinical practice.”
“OS for DUO-O presented this am in front line ovarian cancer.
- The role of durvalumab remains unclear as the benefit appears driven by olaparib
- In BRCAwt/HRD+, mPFS of 45 months is amazing for olaparib/bev/durva but – what is role of durva here? This seems to confirm using olaparib/bev
- Why did this very prolonged PFS not even lead to a hint of OS? All cross over to PARPi in later lines and more effective post progression therapies?
- HRD test neg remains a molecular subtype of high unmet need. PARPi is not effective here and we need to move on based on biolog.”
“Richard Finn presents the results of phase 3 IMbrave152/SkYSCRAPER-14 study at ESMO25 Anti-TIGIT tiragolumab does not add benefit to atezolizumab-bevacizumab for patients with advanced HCC.”
“Improved OS with ADT+enza in high risk BCR (biochemical recurrent) prostate cancer New standard of care but important to reconcile the data with the results of PRESTO AFT19 (apalutamide) and integration in current landscape (PSMA, MDT).”
“In hrBCR prostate cancer, EMBARK (LBA87) shows:
- Enza + LHRH: HR 0.60 → 40% OS benefit vs LHRH alone
- Enza mono → trend but NS
- Both arms improved PFS2, SSEs & delay to new therapy
8-year OS ≥ 79% for combo arm.”
“Had a wonderful time at the ESMO Young Oncologists event in Berlin! An inspiring evening full of collaboration, new friendships, and shared passion for oncology research. Grateful to be part of this vibrant community shaping the future of cancer care.”
“The super Teresa Profeta presenting today at ESMO25 a pivotal study on financial toxicity reported by patients enrolled in phase 1 clinical trials inItaly!”
“Today is shaping up to be an incredible day here in Berlin 🇩🇪 full of inspiring sessions and networking moments you don’t want to miss.
Day 3 at ESMO25
The morning kicked off with a Mini Oral Session in Gynaecological Cancers, followed by ESMO Resilience Task Force Forum.
Also, don’t forget about two exciting events happening tonight!
ESMO GI Round with Dr. Yelena Janjigian and colleagues, bringing together leading experts to discuss the latest breakthroughs in gastrointestinal oncology.
And the OncoDaily Party – a great opportunity to connect, share ideas, and celebrate the collaborative spirit that drives our oncology community… and of course also to dance and have drinks.
If you haven’t received an invitation yet, consider this your invite!
Please register for both events and come join us.
Once you’ve registered, send me a quick message and I’ll share the location details with you directly.
See you tonight!”
“Delighted to be part of the ESMO Ambassadors team at ESMO25!
Let’s connect and discuss the latest news here in Berlin >>> and beyond!”
“Time for Italian Pride super Maria Vittoria Dieci at ESMO25 presenting TILs data from the ABRAVE trial.”
“Fantastic session by Chris Booth at ESMO25
- Req real investment (~$3–4k/pt) – cost effective
- Key Q – where should they sit? In cancer centres?
- Offsite/community centres?
- Exercise as “adjuvant” in ESMO Living Guidelines It’s time to IMPLEMENT.”
“Learned so much from this ESMO25 overview of existing ADCs in bladder cancer by Andrea Necchi in a session hosted Silke Gillessen
and Enrique Grande. The sheer number of trials examining ADCs in bladder cancer is mind-boggling, incl multiple phase 3s.”
“Hot Off The Press. Just published in conjunction with presentation
Results of:
- OptiTROP-Lung04 phase 3 trial of:
- Sacituzumab tirumotecan (TROP2 ADC) VS Chemotherapy in advanced EGFR mutant non-small cell LungCancer after progression on TKI
- Statistically Significant Improvement in:
- OverallSurvival (OS) &
- ProgressionFreeSurvival (PFS).”
“Thankful to ESMO for the opportunity to present our study with co-authors Kristina Jenei, Dr Mark Lythgoe at ESMO25 on the state of the global medical oncology workforce.
We identified a total of 82,995 medical oncologists in practice across the globe. Disparities exist in accessing an oncologist particularly in lower middle- and low-income countries.”
Follow the latest ESMO 2025 news on OncoDaily.
You can also find Part 1 of ESMO 2025.
Part 2 of ESMO 2025.
